Meguro T
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1994 Jul;69(4):995-1009.
An immunoradiometric assay (IRMA) of human hemoglobin-haptoglobin complex (Hb-Hp complex) was established for the purpose of clinical application as a new fecal occult blood test. This IRMA reacted with free human Hb and Hp as well as Hb-Hp complex and its measurable range was 3.125 through 800 ng/ml. Its cross-reaction with other animal Hb and serum was little enough to neglect. The immunoreactivity of Hb-Hp complex was more stable than that of free Hb in incubation with gastric juice and fecal extracts. Of 48 stools from the patients with colorectal cancer, 44 (91.7%) gave positive (above 10 ng/ml in fecal extract) test in Hb-Hp complex-IRMA, whereas 35 (72.9%) (p < 0.05) gave positive result (above 10 ng/ml in fecal extract) in Hb-IRMA. At proximal site of cancer, positive rate of Hb-Hp complex in feces was significantly high (p < 0.05) compared with Hb. Of 64 stools from the patients with colorectal adenomas, 56 (87.5%) gave positive test in Hb-Hp complex, whereas 46 (71.9%) (p < 0.05), 28 (43.8%) (p < 0.01) and 33 (51.5%) showed positive in Hp, Hb and Guaiac test, respectively. In every size and site of adenoma, fecal Hb-Hp complex showed significantly high (p < 0.01) positivity compared with Hb and Guaiac test. These results suggest that the measurement of Hb-Hp complex in fecal extracts may be a useful tool for the early detection of lower gastrointestinal diseases.
为了作为一种新型粪便潜血试验应用于临床，建立了人血红蛋白-触珠蛋白复合物（Hb-Hp复合物）的免疫放射分析（IRMA）方法。该IRMA可与游离的人Hb、Hp以及Hb-Hp复合物发生反应，其可测量范围为3.125至800 ng/ml。它与其他动物Hb和血清的交叉反应小到可以忽略不计。在与胃液和粪便提取物孵育时，Hb-Hp复合物的免疫反应性比游离Hb更稳定。48例结直肠癌患者的粪便样本中，44例（91.7%）在Hb-Hp复合物IRMA检测中呈阳性（粪便提取物中高于10 ng/ml），而35例（72.9%）（p<0.05）在Hb-IRMA检测中呈阳性结果（粪便提取物中高于10 ng/ml）。在癌症近端部位，粪便中Hb-Hp复合物的阳性率与Hb相比显著更高（p<0.05）。64例大肠腺瘤患者的粪便样本中，56例（87.5%）在Hb-Hp复合物检测中呈阳性，而46例（71.9%）（p<0.05）、28例（43.8%）（p<0.01）和33例（51.5%）分别在Hp、Hb和愈创木脂试验中呈阳性。在腺瘤的各个大小和部位，粪便Hb-Hp复合物的阳性率与Hb和愈创木脂试验相比均显著更高（p<0.01）。这些结果表明，检测粪便提取物中的Hb-Hp复合物可能是早期发现下消化道疾病的一种有用工具。
